FISCAL YEAR 2025, CONFIRMATION OF STRATEGIC TRANSFORMATION 9% increase in annual revenue to €168 millionDeployment of the Group's strategy: Proprietary products: 35% of revenueInternationalization: 42% of revenue generated outside France Strengthening of activities in Italy with the acquisition of Quimark and the assets of the Life Sciences unit of Voden Medical Instruments Spa Paris, January 27, 2026 - 5:40 p.m. - Eurobio Scientific (FR0013240934, ALERS), a leading French group in in vitro medical diagnos ...

Core Insights - Eurobio Scientific reported consolidated results for the first half of fiscal year 2025, showing a revenue increase of 10.4% compared to the same period in 2024, driven by recent acquisitions and a higher share of proprietary products [2][5][7]. Financial Performance - Revenue reached €81.2 million, up from €73.5 million in the first half of 2024, with a comparable growth of €4.5 million (+6.1%) when excluding acquisitions [4][5]. - Adjusted gross margin improved by 14% to €38.2 million, reflecting a gross margin of 47.4%, up from 45.6% in the previous year [4][10]. - EBITDA decreased to €13.2 million from €13.9 million year-over-year, while operating income fell to €10.3 million from €11.2 million [12]. - Net income dropped by 40% to €2.4 million compared to €4 million in the first half of 2024 [13]. Cost Structure - Cost of goods sold increased by 8% to €43 million, while research and development expenses decreased by 27% to €2.1 million [4][11]. - Sales and marketing expenses surged by 52% to €18.1 million, attributed to strengthening sales teams and scope effects from acquisitions [4][11]. - General and administrative expenses remained stable at €7.7 million, including costs related to the transfer of production lines [11]. Cash Flow and Debt - Free cash flow declined to €4.4 million, impacted by changes in working capital and net investment flows [14]. - As of June 30, 2025, the company had cash and cash equivalents of €26.7 million and financial debt of €11.3 million, resulting in net debt of €2.2 million [15]. Strategic Outlook - Eurobio Scientific aims to increase the share of proprietary products to around 50% of its revenue over the next four years, focusing on product development and international expansion [16].

Core Business Growth - Eurobio Scientific reported a revenue increase of 19% to €154.2 million in 2024, compared to €130 million in 2023, with organic growth at 9% [4][5][6] - Proprietary products accounted for 31% of total sales, remaining stable compared to the previous year, while international sales represented 41% of group revenue, up from 38% in 2023 [5][6] Financial Performance - Total operating income rose by 19% to €154.9 million, with a gross margin of 46.6%, down approximately 1% from 2023 due to pressure on margins and challenges faced by some European subsidiaries [4][7] - Adjusted EBITDA was €27.7 million, a slight increase from €27.3 million in 2023, while operating income was stable at €22.1 million [10][11] Cost Management - Research and development expenses decreased to €4.6 million, primarily due to reduced activity in France, while marketing and sales expenses increased by €10.1 million, driven by strengthening sales teams and new acquisitions [8] - General and administrative expenses rose by €1.8 million, attributed to new premises and acquisitions [8] Strategic Developments - The company completed the acquisition of EndoPredict® and Prolaris® in August 2024, generating sales of €3.8 million, although this was a 10% decline compared to 2023 [9] - Eurobio Scientific is focused on strategic priorities including the development of proprietary products, internationalization, and market expansion to enhance growth in sales and margins [16] Cash Flow and Debt Management - Free cash flow for 2024 was €6 million, with cash flow from operations amounting to €16.7 million [12][13] - At the end of December 2024, the company had cash and cash equivalents of €23.1 million and net debt of €3.9 million [15]